Overview

A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2020-02-18
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes that have already been treated with basal insulin.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin, Globin Zinc
Insulin, Long-Acting